Adagio Medical Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Adagio Medical Holdings, Inc. (ADGM) on September 8, 2025, reporting events occurring on September 5, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Laguna Hills, California. The filing primarily addresses executive leadership changes within the finance function.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
- Appointment of CFO: The Board appointed Deborah Kaster, the Company's current Chief Business Officer (CBO), as Chief Financial Officer (CFO), Principal Financial Officer, and Principal Accounting Officer, effective September 5, 2025.
- Departure of Interim CFO: Daniel George stepped down from his roles as Interim CFO, Principal Financial Officer, and Principal Accounting Officer on the effective date.
- Expanded Responsibilities: Ms. Kaster will now oversee both business development/corporate strategy and financial operations (accounting, treasury, financial planning).
Compensation, Outlook, and Risks
The filing details an amended offer letter for Ms. Kaster with the following terms:
- Base Salary: $366,000 annually, paid semi-monthly.
- Performance Bonus: Eligible for an annual discretionary performance and retention bonus of up to 40% of base salary.
- Financing Incentive: An immediate salary increase of no less than 4% is triggered upon the successful closing of an equity financing raising at least $5 million in gross cash proceeds.
- Equity Grant: Options to purchase 819,000 shares granted in April 2025. Vesting is split into 728,000 time-based shares (25% on April 1, 2026, then monthly) and 91,000 shares vesting immediately upon a Change in Control with consideration exceeding $250 million.
- Severance: In the event of a "Qualifying Termination," Ms. Kaster is entitled to 6 months of base salary and a prorated bonus. If termination occurs within a specific window surrounding a Change in Control, severance increases to 12 months of base salary plus a lump sum equal to the target annual bonus.
The filing does not provide specific guidance, outlook, or risk factors beyond the standard disclosure that the offer letter summary is qualified by the full text to be filed in the upcoming 10-Q.
Investor Verification Checklist
- Verify the Company's current cash position and ability to fund the new CFO's salary and potential equity financing triggers.
- Review the upcoming Form 10-Q for the nine months ended September 30, 2025, to obtain the full text of the Amended Offer Letter and updated financial statements.
- Monitor for announcements regarding the $5 million equity financing required to trigger the salary increase.
- Assess the impact of the leadership transition on the Company's financial reporting and investor relations strategy.